What a Name Costs

Mid-sentence, a Merck spokesperson cut off a journalist before the word could land: “It’s not a vaccine — it’s an individualized neoantigen therapy.” That interruption, reported by MIT Technology Review, is now the cleanest signal of where the global mRNA industry stands in 2026: doing breakthrough science under a borrowed vocabulary.

The mechanism behind the correction is this. Moderna sequences a patient’s tumor cells, identifies the ugliest surface molecules — neoantigens — encodes them in an mRNA shot, and instructs the immune system to destroy any cell wearing those markers. It is, mechanistically, nearly identical to the COVID-19 vaccine platform. What changed is not the biology. What changed is the political cost of the word.

←TODAY: Moderna and Merck’s INT halved melanoma recurrence deaths in 2025 trial data — but the word “vaccine” has vanished from the paper’s main text.
→3012: In Zurich-3012, a platform that trains the immune system to destroy arbitrary targets is infrastructure, not a product category — naming debates belong to an earlier century.
Fulcrum: The gap between what a technology is and what it can safely be called is where political risk becomes an engineering constraint.

Moderna stopped using “cancer vaccine” in regulatory filings in 2023, when the Merck partnership formalised the rebrand to individualized neoantigen therapy (INT). The CEO framed it as better describing the program’s goal. The logic is not entirely dishonest: patients already have cancer, so INT addresses an existing condition rather than preventing future infection — a genuine clinical distinction. But as Kyle Holen, head of Moderna’s cancer program, told attendees at BIO 2025 in Boston last summer: “Vaccines are maybe a dirty word nowadays.” The subtext wrote itself.

The system pressure behind the rebrand is structural. Under RFK Jr.’s tenure at HHS, federal support for mRNA vaccine projects has been systematically unwound — including a $776 million Moderna bird flu vaccine contract, canceled outright. By January 2026, Moderna was warning publicly that it might have to halt late-stage infectious disease vaccine programs altogether. The INT program, so far, has escaped similar political targeting. The rebrand is working, at least as a shield.

BioNTech’s parallel pivot confirms this is not a Moderna-specific calculation. The Mainz-based firm — whose ties to European and Swiss biotech ecosystems run deep — shifted its own language from “neoantigen vaccine” in 2021 to “mRNA cancer immunotherapies” in its current reporting, as the deep-research notes corroborate. Neither firm is retreating from the science. Both are retreating from the label. Whether the European move is preemptive political hedging or genuine regulatory precision around EMA classification pathways remains an open question — one Swissmedic and major Swiss oncology players like Roche and Novartis will eventually need to answer as INT approaches approval stages.

The trade-off is real and has a human cost. Ryan Sullivan, a physician at Massachusetts General Hospital enrolling patients in Moderna’s trials, told MIT Technology Review that the rebrand risks patients declining cancer treatment because they see the word “vaccine” — or, inversely, that informed consent becomes murkier when a mechanism is deliberately obscured by softer language. “You have to call it what it is,” Sullivan said. Lillian Siu, medical oncologist at Princess Margaret Cancer Centre in Toronto, takes the opposite position: name change is acceptable “if it allows the research to continue.” Both are right. That’s the failure mode.

Atelier: For PAZ readers, the Moderna/Merck episode is a systems lesson that scales beyond pharma: when a technology is renamed to survive its regulatory or political environment, the classification layer becomes load-bearing. In AEC, we know this — whether a parametric skin is “structure” or “cladding” determines the engineer of record, the approval path, and the insurance exposure. Terminology is not decoration; it is governance infrastructure. The question to bring to your team: which of your current tools or workflows are one political cycle away from being reclassified?

The INT results are landmark — a halved mortality risk in advanced melanoma post-surgery is not a footnote. Read the February 2026 paper; note that the word “vaccine” appears only in the footnotes, in titles of old patents. Then ask what else you are reading where the naming has already been quietly renegotiated before it reached your desk.

Source: MIT Technology Review